119 related articles for article (PubMed ID: 38302377)
21. Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer.
Pasquier D; Hadj Henni A; Escande A; Tresch E; Reynaert N; Colot O; Lartigau E; Betrouni N
Sci Rep; 2018 Jul; 8(1):10407. PubMed ID: 29991748
[TBL] [Abstract][Full Text] [Related]
22. Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer.
Luo Y; Li M; Qi H; Zhao J; Han Y; Lin Y; Hou Z; Jiang Y
World J Surg Oncol; 2018 Jun; 16(1):107. PubMed ID: 29890979
[TBL] [Abstract][Full Text] [Related]
23. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K
Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885
[TBL] [Abstract][Full Text] [Related]
24. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation.
Geara FB; Bulbul M; Khauli RB; Andraos TY; Abboud M; Al Mousa A; Sarhan N; Salem A; Ghatasheh H; Alnsour A; Ayoub Z; Gheida IA; Charafeddine M; Shahait M; Shamseddine A; Gheida RA; Khader J
Radiat Oncol; 2017 Sep; 12(1):149. PubMed ID: 28882187
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
[TBL] [Abstract][Full Text] [Related]
26. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
27. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.
Pickles T; Keyes M; Morris WJ
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):43-9. PubMed ID: 19570619
[TBL] [Abstract][Full Text] [Related]
28. The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients.
Onal C; Erbay G; Oymak E; Guler OC
Radiother Oncol; 2023 Jul; 184():109677. PubMed ID: 37084886
[TBL] [Abstract][Full Text] [Related]
29. Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy.
Sun Q; Yang YZ; Yang P; Li YH; Cao Y; Chen D; Zhang Y
Int Urol Nephrol; 2023 Sep; 55(9):2215-2224. PubMed ID: 37306931
[TBL] [Abstract][Full Text] [Related]
30. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
[TBL] [Abstract][Full Text] [Related]
31. PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalation.
McDonald AM; Jacob R; Yang ES; Dobelbower MC; Vanlandingham S; Fiveash JB
Urol Oncol; 2014 Jul; 32(5):687-93. PubMed ID: 24656630
[TBL] [Abstract][Full Text] [Related]
32. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
33. Head-to-head comparisons of [
Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
[TBL] [Abstract][Full Text] [Related]
34. Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.
Rijksen BLT; Pos FJ; Hulshof MCCM; Vernooij RWM; Jansen H; van Andel G; Wijsman BP; Somford DM; Busstra MB; van Moorselaar RJA; Kaa CAH; van Leenders GJLH; Hamberg P; van den Berkmortel F; Fütterer JJ; Kiemeney LA; van Oort IM; Aben KKH
Eur Urol Focus; 2021 Mar; 7(2):332-339. PubMed ID: 31748122
[TBL] [Abstract][Full Text] [Related]
35. Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.
Hötker AM; Mazaheri Y; Zheng J; Moskowitz CS; Berkowitz J; Lantos JE; Pei X; Zelefsky MJ; Hricak H; Akin O
Eur Radiol; 2015 Sep; 25(9):2665-72. PubMed ID: 25820537
[TBL] [Abstract][Full Text] [Related]
36. Multiparametric Magnetic Resonance Imaging of the Prostate: Repeatability of Volume and Apparent Diffusion Coefficient Quantification.
Fedorov A; Vangel MG; Tempany CM; Fennessy FM
Invest Radiol; 2017 Sep; 52(9):538-546. PubMed ID: 28463931
[TBL] [Abstract][Full Text] [Related]
37. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
38. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
39. Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer.
Kim AY; Kim CK; Park SY; Park BK
AJR Am J Roentgenol; 2014 Dec; 203(6):W645-50. PubMed ID: 25415730
[TBL] [Abstract][Full Text] [Related]
40. Can
Chen M; Zhuang J; Fu Y; Guo S; Zang S; Ai S; Qiu X; Wang F; Guo H
J Urol; 2021 Apr; 205(4):1082-1089. PubMed ID: 33207140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
